142 related articles for article (PubMed ID: 22730513)
21. [Management of adults presenting with a thrombocytosis].
Viallard JF
Rev Med Interne; 2010 Dec; 31 Suppl 3():S333-8. PubMed ID: 21035235
[No Abstract] [Full Text] [Related]
22. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
[TBL] [Abstract][Full Text] [Related]
23. [Transformation into chronic myelomonocytic leukemia in a patient with primary myelofibrosis associated with severe hypoplasia: report of an autopsy case].
Yamazaki Y; Horiguchi-Yamada J; Ochi K; Nakada S; Nemoto T; Inaba S; Yamada H
Rinsho Ketsueki; 1995 Apr; 36(4):347-52. PubMed ID: 7783340
[TBL] [Abstract][Full Text] [Related]
24. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
25. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
26. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
Martínez-Trillos A; Gaya A; Maffioli M; Arellano-Rodrigo E; Calvo X; Díaz-Beyá M; Cervantes F
Ann Hematol; 2010 Dec; 89(12):1233-7. PubMed ID: 20567824
[TBL] [Abstract][Full Text] [Related]
28. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
Bowyer SE; White AM; Ransom DT; Davidson JA
Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
[No Abstract] [Full Text] [Related]
29. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
[TBL] [Abstract][Full Text] [Related]
30. Denosumab for tumor-induced hypercalcemia complicated by renal failure.
Bech A; de Boer H
Ann Intern Med; 2012 Jun; 156(12):906-7. PubMed ID: 22711097
[No Abstract] [Full Text] [Related]
31. Malignant hypercalcemia.
Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
[TBL] [Abstract][Full Text] [Related]
32. [A case of myelofibrosis that developed polycythemia vera following treatment with ranimustine and then acute myelogenous leukemia (M0)].
Harashima S; Okamura T; Umeno M; Takaki K
Rinsho Ketsueki; 1996 Aug; 37(8):713-8. PubMed ID: 8827883
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of essential thrombocythemia evolving into agnogenic myeloid metaplasia with interferon-alpha.
Kikawa Y; Fukumoto Y; Obata K; Tamura S; Takeuchi M; Tanizawa A; Mayumi M
J Pediatr Hematol Oncol; 1998; 20(5):463-6. PubMed ID: 9787320
[TBL] [Abstract][Full Text] [Related]
34. Plasma cell leukemia with myelofibrosis.
Murayama T; Matsui T; Hayashi Y; Taniguchi T; Ito M; Natazuka T; Imoto S; Iwata N; Isobe T; Ito H
Ann Hematol; 1994 Sep; 69(3):151-2. PubMed ID: 8086511
[TBL] [Abstract][Full Text] [Related]
35. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review.
Kallas M; Green F; Hewison M; White C; Kline G
J Clin Endocrinol Metab; 2010 Jul; 95(7):3111-7. PubMed ID: 20427501
[TBL] [Abstract][Full Text] [Related]
36. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
37. Megakaryoblastic transformation of polycythemia vera with hypercalcemia.
Kurosawa M; Iwasaki H
Ann Hematol; 2002 Nov; 81(11):668-71. PubMed ID: 12454709
[TBL] [Abstract][Full Text] [Related]
38. Leukemia with megakaryocytic differentiation following essential thrombocythemia and myelofibrosis. Case report and review of the literature.
Patiño-Sarcinelli F; Knecht H; Pechet L; Pihan G; Savas L; Snyder LM
Acta Haematol; 1996; 95(2):122-8. PubMed ID: 8638441
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
40. Gelatinous bone marrow transformation in a case of idiopathic myelofibrosis: a morphological paradox.
Böhm J; Schmitt-Gräff A
Pathol Res Pract; 2000; 196(11):775-9. PubMed ID: 11186174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
